Bejelentkezés Regisztrálj ingyen

Last updated: 28 May 2024 at 8:39pm EST

Julia Eastland Net Worth



Ms. Eastland HARP stock SEC Form 4 insiders trading

Julia has made over 1 trades of the Harpoon Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently she exercised 2,825 units of HARP stock worth $65,003 on 11 January 2018.

The largest trade she's ever made was exercising 2,825 units of Harpoon Therapeutics stock on 11 January 2018 worth over $65,003. On average, Julia trades about 123 units every 0 days since 2017. As of 11 January 2018 she still owns at least 6,160 units of Harpoon Therapeutics stock.

You can see the complete history of Ms. Eastland stock trades at the bottom of the page.





Julia Eastland biography

Julia Marie Eastland serves as Independent Director of the Company. Ms. Eastland has served as a consultant to Rainier Therapeutics, Inc., an oncology biotechnology company, after serving as its Chief Financial and Business Officer from August 2018 to January 2020. Prior to Rainier Therapeutics, Ms. Eastland served as Chief Business Officer and Chief Financial Officer for Cascadian Therapeutics, Inc., a biotechnology company, from September 2010 through its acquisition by Seattle Genetics in March 2018. Prior to Cascadian, Ms. Eastland served as the Chief Financial Officer and Vice President of Finance and Administration for VLST Corporation, a biotechnology company, from January 2006 to September 2010. Prior to VLST Corporation, Ms. Eastland was the Vice President of Strategic Planning at Dendreon Corporation, a biotechnology company, from October 2000 to October 2005. Prior to Dendreon, Ms. Eastland was the Controller at Amgen, a biopharmaceutical company, from March 1996 to April 1998. Ms. Eastland serves on the Board of Directors of the TSX-listed company Pascal Biosciences Inc. (TSX: PAS).

What is the salary of Julia Eastland?

As the Independent Director of Harpoon Therapeutics, the total compensation of Julia Eastland at Harpoon Therapeutics is $143,402. There are 7 executives at Harpoon Therapeutics getting paid more, with Gerald McMahon having the highest compensation of $1,793,260.



How old is Julia Eastland?

Julia Eastland is 56, she's been the Independent Director of Harpoon Therapeutics since 2018. There are 4 older and 9 younger executives at Harpoon Therapeutics. The oldest executive at Harpoon Therapeutics, Inc. is Gerald McMahon, 65, who is the President, Chief Executive Officer, Director.

What's Julia Eastland's mailing address?

Julia's mailing address filed with the SEC is C/O DYNAVAX TECHNOLOGIES, 2100 POWELL STREET, SUITE 720, EMERYVILLE, CA, 94608.

Insiders trading at Harpoon Therapeutics

Over the last 6 years, insiders at Harpoon Therapeutics have traded over $62,512,704 worth of Harpoon Therapeutics stock and bought 26,100,850 units worth $525,945,967 . The most active insiders traders include & Co., Inc.Merck Sharp & Do..., Ronald Hunt és Bioscience Plc Arix Bioscie.... On average, Harpoon Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $9,736,866. The most recent stock trade was executed by & Co., Inc.Merck Sharp & Do... on 11 March 2024, trading 21,397,205 units of HARP stock currently worth $492,135,715.



What does Harpoon Therapeutics do?

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.



What does Harpoon Therapeutics's logo look like?

Harpoon Therapeutics, Inc. logo

Harpoon Therapeutics executives and stock owners

Harpoon Therapeutics executives and other stock owners filed with the SEC include: